Editor’s Pick

Before the availability of a vaccine for COVID-19, implementing exit strategies that ease social distancing restrictions will probably result in epidemics if a low level of community transmission remains or is imported through travel, as seen with the resurgence in the state of Victoria, Australia in July 2020. A Comment published in The Lancet Infectious Diseases discusses whether the elimination of COVID-19 is possible and what individual countries should do to achieve control.

Comment
Elimination of COVID-19: what would it look like and is it possible?
Anita E Heywood, C Raina Macintyre
DOI: https://doi.org/10.1016/S1473-3099(20)30633-2
The Lancet Infectious Diseases
Published: August 6, 2020

Most Read

Articles
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
DOI: https://doi.org/10.1016/S0140-6736(20)31604-4
The Lancet
Open Access
Articles
Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis
DOI: https://doi.org/10.1016/S0140-6736(20)31142-9
The Lancet, Vol. 395, No. 10242
Open Access
Articles
Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the Global Burden of Disease Study
DOI: https://doi.org/10.1016/S0140-6736(20)30677-2
The Lancet
Open Access
Articles
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
DOI: https://doi.org/10.1016/S0140-6736(20)31605-6
The Lancet
A country level analysis measuring the impact of government actions, country preparedness and socioeconomic factors on COVID-19 mortality and related health outcomes
DOI: https://doi.org/10.1016/j.eclinm.2020.100464
EClinicalMedicine
Open Access
World Report
COVID-19 has “devastating” effect on women and girls
DOI: https://doi.org/10.1016/S0140-6736(20)31679-2
The Lancet, Vol. 396, No. 10247
Cerebral Micro-Structural Changes in COVID-19 Patients – An MRI-based 3-month Follow-up Study
DOI: https://doi.org/10.1016/j.eclinm.2020.100484
EClinicalMedicine
Open Access
Articles
Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study
DOI: https://doi.org/10.1016/S0140-6736(20)31483-5
The Lancet
The Lancet Commissions
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
DOI: https://doi.org/10.1016/S0140-6736(20)30367-6
The Lancet, Vol. 396, No. 10248
Comment
Exaggerated risk of transmission of COVID-19 by fomites
DOI: https://doi.org/10.1016/S1473-3099(20)30561-2
The Lancet Infectious Diseases, Vol. 20, No. 8
Comment
Encouraging results from phase 1/2 COVID-19 vaccine trials
DOI: https://doi.org/10.1016/S0140-6736(20)31611-1
The Lancet
Viewpoint
Particle sizes of infectious aerosols: implications for infection control
DOI: https://doi.org/10.1016/S2213-2600(20)30323-4
The Lancet Respiratory Medicine
Articles

Tocilizumab in patients with severe COVID-19: a retrospective cohort study
DOI: https://doi.org/10.1016/S2665-9913(20)30173-9
The Lancet Rheumatology, Vol. 2, No. 8
Review
COVID-19 in people with diabetes: understanding the reasons for worse outcomes
DOI: https://doi.org/10.1016/S2213-8587(20)30238-2
The Lancet Diabetes & Endocrinology
Correspondence
The need for an independent evaluation of the COVID-19 response in Spain
DOI: https://doi.org/10.1016/S0140-6736(20)31713-X
The Lancet
Personal View
Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
DOI: https://doi.org/10.1016/S1473-3099(20)30484-9
The Lancet Infectious Diseases
Comment
Vitamin D for COVID-19: a case to answer?
DOI: https://doi.org/10.1016/S2213-8587(20)30268-0
The Lancet Diabetes & Endocrinology
Rapid Review
Neurological associations of COVID-19
DOI: https://doi.org/10.1016/S1474-4422(20)30221-0
The Lancet Neurology
Articles
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
DOI: https://doi.org/10.1016/S0140-6736(20)31208-3
The Lancet, Vol. 395, No. 10240
Articles
Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study
DOI: https://doi.org/10.1016/S2468-2667(20)30164-X
The Lancet Public Health
Open Access

Register to receive email updates

Sign up here to be kept up to date on Lancet COVID-19 content.

Register for email updates

×

Related Audio

Videos

• 1
• 2
• 3
• 4

Tutorial on prone positioning with helmet continuous positive airway pressure

Tracheal intubation during the COVID-19 pandemic

Editorial: The urgent need for PPE in the USA

Clinical Picture: Myocarditis in a patient with COVID-19

Infographics

Explore all of our COVID-19 infographics.

Data sharing

The Lancet journals endorse the Wellcome Trust Statement on sharing research data and findings relevant to the 2019 novel coronavirus disease (COVID-19) outbreak.

Useful links

• WHO: Coronavirus disease (COVID-19) outbreak

• Cell Press Coronavirus Resource Hub

• Elsevier’s Novel Coronavirus Information Center

• Elsevier Coronavirus Research Hub

Media queries

For media enquiries in relation to content published below, please contact [email protected].